Published in Int J Endocrinol on April 03, 2013
Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations. World J Gastroenterol (2014) 1.04
Mechanisms Linking Inflammation to Insulin Resistance. Int J Endocrinol (2015) 0.96
Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment. Int J Mol Sci (2013) 0.94
Correlation of Body Mass Index and Serum Parameters With Ultrasonographic Grade of Fatty Change in Non-alcoholic Fatty Liver Disease. Iran Red Crescent Med J (2014) 0.88
Resveratrol ameliorates hepatic steatosis and inflammation in methionine/choline-deficient diet-induced steatohepatitis through regulating autophagy. Lipids Health Dis (2015) 0.86
Pinus densiflora Sieb. et Zucc. alleviates lipogenesis and oxidative stress during oleic acid-induced steatosis in HepG2 cells. Nutrients (2014) 0.81
Mechanisms of Diabetes-Induced Liver Damage: The role of oxidative stress and inflammation. Sultan Qaboos Univ Med J (2016) 0.80
Glucose intolerance and diabetes mellitus in ulcerative colitis: pathogenetic and therapeutic implications. World J Gastroenterol (2014) 0.78
Nonalcoholic fatty liver disease: a frequent condition in type 2 diabetic patients. Wien Klin Wochenschr (2014) 0.76
Therapeutic effects of globular adiponectin in diabetic rats with nonalcoholic fatty liver disease. World J Gastroenterol (2014) 0.76
Multidisciplinary approach to the treatment of obese adolescents: effects on cardiovascular risk factors, inflammatory profile, and neuroendocrine regulation of energy balance. Int J Endocrinol (2013) 0.76
The hepatoprotective and hypolipidemic effects of Spirulina (Arthrospira platensis) supplementation in a Cretan population with non-alcoholic fatty liver disease: a prospective pilot study. Ann Gastroenterol (2014) 0.75
Nonalcoholic fatty liver disease. N Engl J Med (2002) 22.41
Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med (2007) 18.45
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med (2010) 13.33
Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology (2006) 10.05
Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology (2010) 8.05
Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med (2010) 7.12
The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology (2007) 6.68
Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med (2010) 6.45
Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology (2001) 5.07
Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology (2005) 4.86
Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology (2008) 4.28
Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut (2008) 3.88
Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol (2007) 3.83
Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. Hepatology (2010) 3.60
Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology (2007) 3.58
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology (2010) 3.55
Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA (2011) 3.37
Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes (2005) 3.36
Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology (2010) 3.03
Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis (2006) 2.95
Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis (2008) 2.89
Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Hepatology (2009) 2.88
Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol (2007) 2.71
Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology (2009) 2.66
Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology (2003) 2.44
Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol (1997) 2.38
Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia (2008) 2.32
Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol (2012) 2.25
NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity (Silver Spring) (2008) 2.23
Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care (2007) 2.09
Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology (2008) 2.07
Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol (2010) 2.06
Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology (2004) 2.06
Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care (2006) 2.04
Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology (2008) 2.02
The role of adipose tissue and lipotoxicity in the pathogenesis of type 2 diabetes. Curr Diab Rep (2010) 1.98
Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int (2008) 1.90
Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology (2010) 1.86
Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism (2010) 1.77
Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord (1998) 1.76
Health-related fitness and physical activity in patients with nonalcoholic fatty liver disease. Hepatology (2008) 1.74
Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. J Hepatol (2007) 1.69
Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology (2006) 1.65
The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol (2012) 1.61
Nonalcoholic fatty liver disease in type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes (2009) 1.61
A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol (2004) 1.56
Statins and hepatic steatosis: perspectives from the Dallas Heart Study. Hepatology (2006) 1.56
Natural history of NAFLD: remarkably benign in the absence of cirrhosis. Gastroenterology (2005) 1.50
Genetics of alcoholic liver disease and nonalcoholic fatty liver disease. Semin Liver Dis (2007) 1.49
Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut (2004) 1.44
Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology (2007) 1.40
Advanced MRI methods for assessment of chronic liver disease. AJR Am J Roentgenol (2009) 1.39
Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol (2010) 1.37
Impact of fatty liver disease on health care utilization and costs in a general population: a 5-year observation. Gastroenterology (2007) 1.26
High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology (2010) 1.24
Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. Diabetes Care (2007) 1.16
Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. J Hepatol (2010) 1.16
Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes. Am J Physiol Endocrinol Metab (2006) 1.10
Nonalcoholic fatty liver disease and the coronary artery disease. Dig Dis Sci (2010) 1.05
Breath biomarkers and non-alcoholic fatty liver disease: preliminary observations. Biomarkers (2006) 1.05
Cardiovascular risk factors, nonalcoholic fatty liver disease, and carotid artery intima-media thickness in an adolescent population in southern Italy. Am J Epidemiol (2010) 1.02
Effect of pioglitazone therapy on myocardial and hepatic steatosis in insulin-treated patients with type 2 diabetes. J Investig Med (2007) 1.02
Genes and nonalcoholic fatty liver disease. Curr Diab Rep (2008) 1.01
Liver pathology in morbidly obese patients undergoing Roux-en-Y gastric bypass surgery. Obes Surg (2002) 0.98
Potential of incretin-based therapies for non-alcoholic fatty liver disease. J Diabetes Complications (2013) 0.97
Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. Arch Med Sci (2011) 0.96
Effects of N-3 fatty acids on hepatic triglyceride content in humans. J Investig Med (2008) 0.93
Pentoxifylline attenuates methionine- and choline-deficient-diet-induced steatohepatitis by suppressing TNF-α expression and endoplasmic reticulum stress. Exp Diabetes Res (2012) 0.85
Combination drug treatment in patients with non-alcoholic fatty liver disease. World J Hepatol (2010) 0.82
Hepatic steatosis in morbidly obese patients undergoing gastric bypass surgery: assessment with open-system 1H-MR spectroscopy. AJR Am J Roentgenol (2011) 0.78
Weight loss, dietary advice and statin therapy in non-alcoholic fatty liver disease: a retrospective study. Int J Clin Pract (2008) 0.77
Cardiac tamponade as the first manifestation of gastric cancer and remission after chemotherapy. Dig Dis Sci (2001) 0.79
Hematological malignancies are associated with a lower interferon-a blocking activity than solid tumors. Res Commun Mol Pathol Pharmacol (2005) 0.75
Acute renal failure in acute pancreatitis. J Med (1984) 0.75